NCT06914453View on ClinicalTrials.gov

A Randomised Controlled Trial to Compare Two Supraglottic Airway Devices (Ambu AuraGain vs Air Q-3) in Terms of Performance Characteristics.

NACompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

July 26, 2024

Primary Completion Date

January 24, 2025

Study Completion Date

January 24, 2025

Conditions
Oropharyngeal Leak PressureSupraglottic AirwayElective SurgeryGeneral Anaesthesia
Interventions
DEVICE

Air Q-3 Supraglottic Airway Device

Oropharyngeal leak pressure and other performance characteristics including time to insertion, first-pass success rate, ease of orogastric tube (OGT) insertion, laryngeal alignment using a fiberoptic scope, and incidence of postoperative sore throat.

DEVICE

Ambu AuraGain Supraglottic Airway Device

Oropharyngeal Leak Pressure and other performance characteristics including time to insertion, first-pass success rate, ease of orogastric tube (OGT) insertion, laryngeal alignment using a fiberoptic scope, and incidence of postoperative sore throat.

Trial Locations (1)

50603

Department of Anaesthesiology, Faculty of Medicine, Kuala Lumpur

All Listed Sponsors
lead

University of Malaya

OTHER

NCT06914453 - A Randomised Controlled Trial to Compare Two Supraglottic Airway Devices (Ambu AuraGain vs Air Q-3) in Terms of Performance Characteristics. | Biotech Hunter | Biotech Hunter